Inventor · disambiguated record
Elisabeth Nahrwold
Also filed as: NAHRWOLD ELISABETH
13 granted patents·11 pending applications·79 citations·filing 2014–2025
90Inventor score
Top patents by PatentIndex Score
24 records- 0197US10294300B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted May 21, 2019·37 cites·16 claims
- 0296US11591396B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2020·Granted Feb 28, 2023·5 cites·33 claims
- 0394US9765157B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2015·Granted Sep 19, 2017·13 cites·14 claims
- 0493US10683351B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 16, 2020·4 cites·24 claims
- 0591US11692031B2Antibody constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jul 4, 2023·6 cites·18 claims
- 0687US11661462B2Optimized cross-species specific bispecific single chain antibody contructsAMGEN RES MUNICH GMBH·Filed 2015·Granted May 30, 2023·4 cites·12 claims
- 0786US11447567B2Antibody constructs for FLT3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Sep 20, 2022·4 cites·18 claims
- 0884US12435139B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2022·Granted Oct 7, 2025·0 cites·12 claims
- 0983US2025340639A1Antibody constructs for dll3 and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 1082US12297292B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2017·Granted May 13, 2025·2 cites·12 claims
- 1182US10851170B2Antibody constructs for CD70 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 1, 2020·3 cites·18 claims
- 1278US2024166761A1Single chain binding molecules comprising N-terminal ABPAMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 1378US2024400673A1Antibody constructs for msln and cd3AMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 1476US12304952B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 1575US2025333535A1Bispecific single chain antibody construct with enhanced tissue distributionAMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 1674US11884720B2Antibody constructs for MSLN and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Jan 30, 2024·1 cites·23 claims
- 1770US2024174745A1Antibody Constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 1867US2025282863A1Antibody constructs for msln and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 1966US2023272113A1Antibody constructs for flt3 and cd3AMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 2059US2020040099A1Single chain binding molecules comprising N-terminal ABPAMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 2157US2021284748A1Antibody constructs for cd70 and cd3AMGEN RES MUNICH GMBH·Filed 2020·Application pending·0 cites
- 2257US2016122436A1Single chain binding molecules comprising n-terminal abpAMGEN RES MUNICH GMBH·Filed 2014·Application pending·0 cites
- 2347US12258404B2Bispecific antibody construct directed to MUC17 and CD3AMGEN INC·Filed 2018·Granted Mar 25, 2025·0 cites·19 claims
- 2441US2017275373A1Bispecific single chain antibody construct with enhanced tissue distributionAMGEN RES MUNICH GMBH·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →